UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(state or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
Registrant's telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading symbol |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 25, 2021, Kezar Life Sciences, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2021, as amended on June 2, 2021.
Proposal 1: The Company’s stockholders elected the three nominees of the Company’s board of directors to serve as Class III directors until the 2024 annual meeting of stockholders, or until their successors are duly elected and qualified, by the votes set forth in the table below:
|
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Jean-Pierre Sommadossi, Ph.D. |
30,926,997 |
7,462,108 |
5,413,852 |
|
John Fowler |
32,591,571 |
5,797,534 |
5,413,852 |
|
Christopher Kirk, Ph.D. |
32,190,083 |
6,199,022 |
5,413,852 |
Proposal 2: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 by the votes set forth in the table below:
|
Votes For |
Votes Against |
Abstain |
|
43,785,599 |
3,358 |
14,000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
KEZAR LIFE SCIENCES, INC. |
||
|
|
|
|
|
|
|
By: |
|
/s/ Marc L. Belsky |
|
|
|
|
Marc L. Belsky |
|
|
|
|
Chief Financial Officer and Secretary |
Dated: June 30, 2021